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Single photon emission computed tomography (SPECT)
with technetium-99m hexakis 2-methoxyisobutyl isonitrile
was investigated as a method to evaluate the results of
intravenous thrombolytic treatment in 14 patients (11 men
and 3 women) with acute myocardial infarction admitted to
the coronary care unit within 4 h of the onset of symptoms.
All patients received an injection of 740 MBq of the tracer
before starting the thrombolytic therapy, and isonitrile
tomography was performed 3 to 4 h later. The tomographic
study was repeated 5 days after the acute event. The results
of thrombolytic treatment were independently evaluated
taking into account the clinical, electrocardiographic
(ECG) and enzymatic data and the findings of left ventric-
ular and coronary angiography. Furthermore, all patients
were studied with two-dimensional echocardiography on
admission,S days later and 1 month later.
The site and extent of the perfusion defects on admission
At the beginning of the 1980s (1,2), coronary angiography
performed during the first few hours of myocardial infarction
revealed that thrombosis is present in the coronary artery
supplying the ischemic zone and may be considered the
cause of myocardial infarction in the large majority of
patients. This observation led to widespread interest in
thrombolytic therapy of acute myocardial infarction. In the
following years, several clinical trials (3-6) provided con-
vincing evidence that this therapy improves survival, espe-
cially if initiated within the first few hours of the onset of
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scintigraphy were consonant with the ECG and echocardio-
graphic findings. A good correlation could be established
between the 5 day scintigraphic estimate of infarct dimen-
sion and the enzymatic infarct size (r = 0.907, P <
0.00002). The comparison between pre-' and posUhrom-
bolytic treatment images enabled the identification of suc-
cessful and unsuccessful reperfusion even in patients whose
other noninvasive findings were inconclusive. Finally, the
reduction in defect size predicted late functional improve-
ment that was demonstrated by echocardiography per-
formed 1 month later (r =0.89, p < 0.00(05).
The results of the study suggest the feasibility and the
possible usefulness of isonitrile tomography in demonstrat-
ing the presence and size of myocardial damage and in
assessing the extent of myocardial salvage after throm-
bolytic therapy in acute myocardial infarction.
(J Am Coil CardioI1990;15:301-14)
symptoms. This favorable outcome was related to the limi-
tation of the extent of infarct size and consequent improve-
ment in left ventricular function (7-15).
On the basis of these data, early thrombolytic therapy has
become standard treatment for patients with acute myocar-
dial infarction. However, because it is difficult to predict and
estimate the effectiveness of therapy in one subject, impor-
tant clinical problems related to the evaluation of the results
of thrombolytic therapy in the individual patient remain
unsolved. These problems involve assessment of the extent
of ischemic myocardium in the acute phase of infarction,
evaluation of the final amount of myocardial necrosis after
thrombolytic treatment and identification of the effects of
reperfusion in terms of reversibly damaged ischemic myo-
cardium (16).
To permit evaluation of the effectiveness of thrombolytic
treatment, an ideal imaging method should be able to detect
0735-1097/90/$3.50
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the involved area before and after treatment (16,17). It would
then be possible to estimate the amount of myocardium at
risk as well as the area of definitively damaged myocardium
and, consequently, the extent of myocardial salvage. In
theory, myocardial perfusion scintigraphy with thallium-201
performed before and after treatment might be a suitable
technique to achieve these results, and several reports
(18-26) have already described its value. However, the use
ofthallium-201 is subject to several limitations: low emission
energy with a high attenuation of the photons by the extra-
cardiac tissues, prolonged half-life and unfavorable decay
modality (which preclude use of high activity doses) and
early redistribution (which implies that the images should
ideally be obtained immediately after the injection, thus
interfering with the immediate start of thrombolytic thera-
py). Furthermore, in most nuclear medicine laboratories,
thallium-201 is not available at all times.
In the last few years, a new class of radiopharmaceutical
agents has been developed, namely, the technetium-99m-
labeled isonitrile derivatives (27-29). Experimental data (30)
with technetium-99m hexakis 2-methoxyisobutyl isonitrile
indicate that this tracer accumulates rapidly in myocardial
cells in direct proportion to regional blood flow and remains
trapped in the viable cells without significant redistribution.
These features make it possible to inject this agent before
beginning thrombolytic therapy and to obtain scintigraphic
images of the preintervention myocardial perfusion up to 3to
4 h later (16,17,31). Thus, myocardial perfusion scintigraphy
can be performed without interfering with the time-depend-
ent therapy.
The present study was designed to investigate if single
photon emission computed (SPECT) tomography with tech-
netium-99m hexakis 2-methoxyisobutyl isonitrile can be
used to evaluate the results of thrombolytic therapy in
individual patients with acute myocardial infarction in terms
of estimation of final infarct size, identification of successful
versus unsuccessful reperfusion and assessment of the ex-
tent of myocardial salvage.
Methods
Study patients. The study group included 14 patients (11
men and 3 women, mean age ± SD 57.4 ± 10.9 years)
admitted to our coronary care unit for chest pain suggestive
of acute myocardial ischemia. The pain lasted >30 min and
was not relieved by the sublingual administration of nitrates.
In all patients, the diagnosis of acute myocardial ischemia
was confirmed by electrocardiographic (ECG) changes
showing ST segment elevation ~O.l mY at the J point in at
least two limb leads or ~0.2 mY in at least two precordial
leads. Patients were included only if the following require-
ments had been fulfilled: 1) there was no history of previous
myocardial infarction or other cardiac disease; 2) there were
no contraindications for thrombolytic treatment; 3) throm-
bolytic therapy could be initiated within 4 h of the onset of
symptoms; 4) complete and adequate visualization of
endocardial wall motion could be obtained with two-
dimensional echocardiography performed immediately after
admission; and 5) informed consent had been obtained from
the patient.
Study protocol. After blood sampling for cardiac en-
zymes and coagulation, a two-dimensional echocardiogram
was performed. In the meantime, patients received an injec-
tion of 740 MBq of technetium-99m hexakis 2-methoxy-
isobutyl isonitrile (Cardiolite) that had been prepared as
soon as the city emergency ambulance coordination center
informed the emergency room physician that a patient with
suspected myocardial infarction was being transported to the
coronary care unit. After pretreatment with 5 to 10 mg of
atenolol intravenously and 325 mg of aspirin orally, intrave-
nous thrombolytic therapy with recombinant tissue plasmin-
ogen activator (rt-PA) (Actylise) was started. The drug was
administered over 3 h at doses of 50, 20 and 20 mg at each
successive hour, with an initial bolus of 10 mg (total dose 100
mg). At the end of the plasminogen activator infusion,
intravenous heparin at 25,000 to 30,000 U/24 h and nitroglyc-
erin at 2 to 4 JL8t'min were started. Apart from these drugs,
standard therapy for acute myocardial infarction, including
opiates for pain, antiarrhythmic drugs and diuretic agents,
was used when necessary.
Within 3 to 4 h of starting thrombolytic therapy, patients
were taken to the nuclear medicine department to undergo
SPECT tomography. The transport of the patient and his or
her stay in the nuclear medicine department were arranged
to ensure close supervision by a cardiologist and two expe-
rienced nurses, constant ECG monitoring and easy availabil-
ity of all resuscitation resources. Five days later, patients
underwent repeat SPECT imaging; a two-dimensional
echocardiogram was performed on the same day.
In the period between the start of thrombolytic therapy
and day 5 after admission, serial determinations of serum
creatine kinase isoenzyme (MB CK) activity and serial
ECGs were performed. Blood samples were drawn every
hour for the first 12 h, every 3 h for the subsequent 12 h,
every 6 h for the next 2 days and every 12 h until day 5.
Twelve lead ECGs were performed every 30 min during
rt-PA infusion and for the next 2 h; subsequent ECGs were
performed at the same time intervals as blood samples were
drawn.
After giving informed written consent, patients under-
went left ventriculography and coronary angiography within
1 week of admission to the hospital. One month after
hospital admission (15 to 20 days after discharge) patients
were reexamined and a 12 lead ECG and two-dimensional
echocardiogram were repeated.
The study protocol was approved by the Committee for
the Clinical Experimentation in our institution.
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Noninvasive assessment of reperfusion. According to stan-
dard criteria (32-36), reperfusion was considered to have
occurred when all the following findings were present in a
strict temporal relation with thrombolytic therapy: abrupt or
rapidly progressive relief of chest pain, reduction of ST
segment elevation with rapid return to the isoelectric line
and early peaking of serum MB CK level (within 12 h of
treatment onset).
Enzymatic and electrocardiographic evaluation. Creatine
kinase isoenzyme activity was measured using an immuno-
logic method with starter reagent (Monotest MB CK NAC-
act.). Using the values of the MB CK curve, infarct size was
estimated as described by Sobel et al. (37) and expressed as
MB CK gram-equivalents.
Twelve lead ECGs were recorded using a Hewlett-
Packard 4700A cardiograph. The evolution of the ECG
pattern was monitored by taking pathologic Q wave devel-
opment into account. The ECG performed on the fifth day
and after 1month were scored according to the 29 point QRS
scoring system proposed by Wagner et al. (38).
Two-dimensional echocardiography. Two-dimensional
echocardiograms were performed using an Atoka SSD-720
echocardiograph equipped with a 3 MHz frequency Atoka
ASU 32-3-M mechanical transducer. Patients were studied
in the left lateral decubitus position. In each study, paraster-
nal long- and short-axis views and apical two and four
chamber views were obtained; in subjects in whom these
views are suboptimal, the subxiphoid window was used.
Images were registered on a Panasonic NGV 10 videore-
corder to enable an accurate study and the definition of the
evolution pattern in each patient. For the purpose of wall
motion analysis, the left ventricle was subdivided into II
segments according to a modification of the method pro-
posed by Edwards et al. (39), with the apex considered as a
single segment. The wall motion pattern of each segment
was visually analyzed ;,y two independent observers who
were unaware of patl ;nt identity, temporal sequence in
which images were acquired and results of other clinical and
graphic data. The wall motion of each segment was classified
as normal or abnormal on the basis of visual impression. The
segment was recognized as asynergic if >50% of its extent
exhibited abnormal wall motion (hypokinesia, akinesia, dys-
kinesia). For each study, an asynergic area extent score was
obtained. This was calculated as the ratio between the
number of segments with abnormal wall motion and the
number of all segments examined. The Spearman rank
correlation coefficient between the estimates of the two
observers was 0.78 (p < 0.01).
Left ventricular and coronary angiography. Angiography
was performed using either the brachial or the femoral
approach. Monoplane left ventricular angiograms were ob-
tained in 30° right anterior oblique and 45° to 60° left anterior
oblique projections. To measure left ventricular wall motion,
end-diastolic and end-systolic endocardial contours were,
respectively, traced in the projected cine film, using the
frames with maximal and minimal ventricular volume from a
normal sinus beat not preceded by a premature beat. Wall
motion pattern was evaluated visually for the presence of
regional asynergy (hypokinesia, akinesia, dyskinesia). Cor-
onary angiograms were recorded in multiple projections,
including cranial and caudal views of the left coronary
artery. The infarct-related vessel was identified on the basis
ofthe location of: I) ST elevation on the ECG, 2) perfusion
defect on the scintigram, 3) asynergic wall motion on the
echocardiogram and ventriculogram, and 4) coronary vessel
anatomy; the vessel was subsequently evaluated for patency
according to the Thrombolysis in Myocardial Infarction
(TIMI) criteria (40). Patency was considered present when
grade 2 or 3 perfusion was recognized. Left ventricular wall
motion and infarct-related coronary artery perfusion status
were independently assessed by two observers who were
unaware of patient identity and other clinical and graphic
data. In all cases, complete interobserver agreement was
achieved.
Single photon emission computed tomography. SPECT
imaging was performed using a double-head gamma camera
(Rotacamera, Siemens) equipped with ultrahigh resolution
collimators, with a 15% window about the 140 keY of the
technetium-99m emission photopeak. The gamma camera
was interfaced with a computer (Hewlett-Packard A900) and
the acquisition was performed in step and shot mode, 360°
rotation are, 90 projections each lasting 10 s, on 64 x 64
matrices. Tomographic images were reconstructed with an
iterative algorithm (seven iterations) using the conjugated
gradient method (41) and taking into account the spatial
system response to compensate for resolution losses due to
depth (42). The cast of transaxial slices was then used to
generate oblique sections, rearranged along the vertical and
horizontal long axes and the short axis of the left ventricle
(43). Computation time for an entire study was about 3 h.
Previous experience using phantoms with our acquisition
and reconstruction procedure gave a value of 8 mm for the
full width half maximum of the point spread function at a
depth comparable with that of the heart (42). A visual
example of the difference in resolution power of our method
with respect to the conventional filtered backprojection is
shown in Figure I.
The myocardial wall/chamber and myocardial wall/lung
count ratios in a midventricular slice (short axis) were,
respectively, 5.9 ± 0.3 and 3.55 ± 0.7 (mean values ± SD),
with a count density in the normally perfused myocardium of
11,230 ± 3,820 counts/em3. After a qualitative overview of
the images to identify the site of the area involved, quanti·
fication of the amount of myocardial tissue included in the
perfusion defects was made using the short axis view images
with a method similar to that employed by Tamaki et al. (44).
The original I pixel thick sections (dimensions of the pixel in
the 64 x 64 matrix = 6 x 6 mm) were added to obtain 6 (or,
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Figure 1. Thoracic transaxial tomo-
graphic slices at midventricular level.
Left, Reconstruction using the filtered
backprojection (Hann filter, cutoff fre-
quency 0.5 cycles/pixel). Right, Recon-
struction with the iterative algorithm
according to our method. The improve-
ment in image quality is easily appre-
ciable when the reduced thickness of
the ventricular walls and the sharp con-
trast between uptaking myocardium
and background are considered.
when necessary, 7) 3 pixel thick slices (slice thickness 18
mm). They were subsequently interpolated in an expanded
256 x 256 matrix (dimensions of the pixel 1.5 x 1.5 mm).
Because of the features of the tracer and of the acquisition
and reconstruction procedures, images of good quality could
be achieved with high target to background ratio and c1ear-
cut contrast between perfused and nonperfused territories.
Therefore, the subtraction of a fixed percent of the maximal
radioactivity to help identify the myocardial edges was not
performed.
Regions of interest defining the contours of both the
perfused myocardium and the uptake defect areas were
manually drawn by visual inspection using a computer-
assisted procedure, and the included number of pixels was
automatically calculated (Fig. 2). Manual drawing also al-
lowed us to eliminate small artifacts by regularizing the
profiles of the perfused regions. The contours of the uptake
defect areas were drawn so as to complete the shape of the
ventricular wall, taking into account the curvature of the left
ventricle and the thickness of surrounding perfused regions.
Particular care was used for the inferior wall because of the
possibility of significant spillover from splanchnic struc-
tures, which may be encountered in some instances. After
adding together the pixels of the normal myocardium and
uptake defects of all the slices, the number of three-
dimensional image elements (voxel) was multiplied by the
volume of each element: 1.5 x 1.5 x 18 mm = 40.5 mm3.
The resulting volume was finally multiplied by the specific
weight of the heart muscle (1.05 glcm3). The size of the
perfusion defect area could, therefore, be expressed both as
amount in grams of involved tissue and as a percent of total
left ventricular mass. Each set of images was evaluated
independently by two observers, and the mean of the two
values was employed for the final evaluation. Interobserver
variability never exceeded 5%. The estimated extent of
perfusion defects on both the admission and 5 day studies
was compared, and the variation was expressed as percent
of the initially involved area.
Statistical analysis. Comparison of the enzymatic and
scintigraphic infarct size and of scintigraphic and echocar-
diographic results was performed by using both the Pearson
correlation coefficient and linear regression. The level of
significance was fixed at p < 0.05.
Results
Clinical course. The delay between the onset of symp-
toms and admission to the coronary care unit ranged from 1
to 3 h (mean 1.9 ± 0.7). The delay between admission to the
coronary care unit and start of thrombolytic treatment after
technetium-99m hexakis 2-methoxyisobutyl isonitrile injec-
tion ranged from 15 to 35 min (mean 22.3 ± 5.6). Before
being transported to the nuclear medicine department to
perform the first scintigraphic study, two patients (cases 2
and 15) had episodes of sustained ventricular tachycardia
that were abolished by intravenous administration of
lidocaine. No complications occurred that could be attrib-
uted to patient transport to the nuclear medicine department
or to scintigraphic image acquisition. During the stay at the
nuclear medicine department, one patient with inferior in-
farction (Case 6) developed high grade atrioventricular (AV)
block that was treated by temporary ventricular pacing. One
patient (Case 10) died on the third day after admission
because of cardiogenic shock resulting from extension of the
infarction and, thus, could not be evaluated. No other
patient had recurrence ofchest pain or a new ischemic attack
or was subjected to resuscitation maneuvers after admission.
Clinical, graphic and angiographic findings (Tables 1 and
2). Table 1shows the evolution of symptoms, ECG changes
and cardiac enzymes after thrombolytic treatment. On the
basis of these data and taking into account the previously
mentioned criteria, reperfusion could be inferred in 3 of the
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Figure 2. PaHent 12. Short-axi~ images (from
left to right: basal, midventricular and subapi-
cal slices). A, in the prethrOinbolytic treat-
ment images, a cIearctit anterolateral perfu-
sion-defect is shown (top row, arrows). B, In
the 5 day images, a noteworthy reduction in
the defect can be appreciated (top row, ar--
rows). In the respective bottom rows, the
computer-assisted, manually drawn perfused
and nonperfused areas (arrows) are shown.
13 patients (Cases 1, 5 and 7), whereas the findings in
another 3 patients (Cases 3, 4 and 8) aliowed us to assume
the absence of significant reflow. In the remaining seven
patients, data were conflicting and no reliable conclusion
about the occurrence of reperfusion could be drawn.
The evolution of ECG changes after admission showed
the appearance of abnormal Qwaves in II patients, rever-
sion to normal in 2 patients (Cases 1 and 12) (Table 2).
Two-dimensional echocardiography performed immedi-
ately after admission demonstrated one or more asynergic
segments in all patients (Table 2). In the 5 day echocardio-
gram, a reduction in asynergic area extent score as com-
pared with the admission pattern was noted in only one
patient (Case 1).
Left ventriculography showed a clear wall motion abnor-
mality of the involved area in 11 subjects and a normal
pattern in only 2 patients (Cases 1 and 12); according to the
coronary angiographic findings, the infarct-related vessel
was patent in 9 patients (Cases 1,4,5-7,9, 11, 12 and 14) and
closed in 4 (Table 2).
The results of the delayed evaluation (1 month after the
acute episode) demonstrated no variations in the ECG
pattern in 12 patients; in only I patient (Case 7) was a
reduction in QRS score observed (Table 2). In contrast,
echocardiography showed a clear reduction in the extent of
wall motion abnormalities in seven patients (Cases l, 5-7, 9,
11 and 12), with a decrease in asynergic area extent score
ranging from 33% to 100%; in the remaining six patients the
wall motion pattern was unchanged (Table 2).
Scintigraphic evaluation (Table 3). In the first scinti-
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Table 1. Clinical Features and Evolution of Symptoms, Electrocardiographic Changes and Cardiac Enzymes After Thrombolytic
Treatment in 14 Patients
Time Intervals (h) between:
Enzymatic
Onset of Start of Start of Estimate of
Symptoms Treatment Treatment and MBCK Time to MB CK Infarct Size
Case Age (yr)1 and Start of and Relief Beginning of ST Peak Peak After Start (MB CKgram
No. Gender Treatment of Pain Normalization (units) of Treatment (h) equivalents)
I 56/M I I I 55 6 9.5
2 581M 2 5 5 456 9 65
3 651M 2 6 3 401 15 41
4 61/M 3 6 Never 200 15 39
5 58/M 2 I 2 350 4 37.8
6 64IM I 2 Never 170 9 30
7 37/F 2 I 2 510 4 27
8 58/M 3 4 Never 91 21 25
9 63/F I 2 I III 15 14.3
10 801M 2 4 Never 158 18
11 60/M 2 2 6 300 9 30.6
12 461M 1 1 4 88 18 9.5
13 59/F 2 4 5 429 12 46.3
14 391M 3 4 6 153 12 33
F = female; M = male; MB CK = serum creatine kinase MB isoenzyme.
graphic study, all patients presented with a clear perfusion
defect. The location and extent of the defect were consonant
with the ECG and echocardiographic findings. In the 5 day
scintigraphic study, seven patients (Cases 1,5,6,7,9, II and
12) showed a remarkable reduction in the perfusion defect,
with a decrease in involved left ventricular mass ranging
from 51% to 73% in comparison with the initial images (Fig.
3). In contrast, the other six patients had only a negligible
reduction in the extent of the perfusion defect, with a
decrease ranging from I% to 8% of the initial defect size
(Fig. 4). Infarct size estimated on the basis of the 5 day
scintigraphic images was compared with the amount of
necrotic tissue measured using the MB CK curves and a
good correlation was found (r = 0.907, p < 0.00002) (Fig. 5).
The percent decrease in the perfusion defect size between
the first and second scintigraphic studies showed a good
correlation with the reduction of the asynergic area extent
score evaluated by comparing the results of the admission
echocardiographic examination with those of the delayed
control study performed I month after the acute episode (r =
Table 2. Electrocardiographic, Echocardiographic and Angiographic Findings in 14 Patients
Ventriculography and
Electrocardiogram Echocardiographic Asynergic Area Extent Score Coronary Angiography
QRS Score % Decrease LV Wall Status of
Case Involved Leads (1 month vs. Motion Infarct-Related
No. (admission) 5 Day I Month Admission 5 Day 1 Month admission) Pattern Vessel
I VI-V3 0 0 0.18 0 0 100 Normal Patent
2 II, Ill, aVF 8 8 0.09 0.09 0.09 0 Abnormal Occluded
3 V2-V5 3 3 0.27 0.27 0.27 0 Abnormal Occluded
4 VJ-V, 9 9 0.18 0.18 0.18 0 Abnormal Patent
5 VI-V3 4 4 0.45 0.45 0.09 80 Abnormal Patent
6 VI-V. 2 2 0.27 0.27 0.18 33 Abnormal Patent
7 V2-V. 3 2 0.36 0.36 0.18 50 Abnormal Patent
8 II, Ill, aVF 3 3 0.18 0.18 0.18 0 Abnormal Occluded
9 II. III 6 6 0.36 0.36 0.18 50 Abnormal Patent
10 VI-V. 0.27
II VI-V3 2 2 0.27 0.27 0.09 66 Abnormal Patent
12 I, aVL 0 0 0.09 0.09 0 100 Normal Patent
13 II. III, aVF, V.' V5 5 5 0.18 0.18 0.18 0 Abnormal Occluded
14 II. III, aVF, V5, V6 4 4 0.18 0.18 0.18 0 Abnormal Patent
LV = left ventricular.
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Table 3. Results of Single Photon Emission Computed Tomography With Technetium-99m Hexakis 2-Methoxyisobutyl
Isonitrile in 14 Patients
Admission 5 Day
% Decrease of
Estimate of Estimate of Defect Extent
Involved %of Left Involved %of Left Between
Case Myocardium Ventricular Myocardium Ventricular Admission and 5
No. Site of Uptake Defect (g) Mass (g) Mass Day Images
I Anteroseptal 29 17.9 7.9 4.9 73
2 Inferolateral 67.3 23.2 65.6 22.7 2
3 Anterolateral and apex 33.2 16 31.5 15.2 5
4 Anteroseptal and apicolateral 52.3 32 49.4 30.2 6
5 Anteroseptal and apex 55.2 41.7 27.3 20.6 51
6 Anteroseptal and apex 49.8 38.7 20.8 16.1 58
7 Anteroseptal and apex 39.5 28.7 12.6 9.2 68
8 Inferolateral 25 17.6 23.8 16.7 5
9 Inferolateral 22.6 19.8 9 7.8 61
10 Anteroseptal and apex 48 29
II Anteroseptal and apex 79.5 36.7 34.7 16 56
12 High lateral 20 8.6 7.4 3.2 63
13 Inferolateral and apex 42.4 18.4 38.9 16.9 8
14 Inferolateral 41.2 18.1 40.9 17.9 I
0.89, p < 0.00(05) (Fig. 6). When the percent decrease in the
perfusion defect size was compared with the echocardio-
graphic evolution in the individual patients, only one of the
seven patients with a significant decrease in perfusion defect
size showed a reduction of asynergic area extent score on
the 5 day echocardiogram, whereas in all these patients
echocardiography performed I month later demonstrated a
reduction of wall motion abnormalities. In contrast, in the
six patients who had a limited or negligible reduction in
perfusion defect size, there was no echocardiographic im-
provement in left ventricular wall motion, even after I month
(Fig. 7).
Discussion
Advantages of technetium·99m isonitrile scintigraphy.
Technetium-99m hexakis 2-methoxyisobutyl isonitrile offers
significant advantages over thallium-201 for myocardial per·
fusion imaging to evaluate thrombolytic therapy: higher
emission energy, shorter half·life, higher administrable ac-
tivity and absence of any significant redistribution, even
several hours after administration (30). The absence of any
significant redistribution allows one to inject the radiophar-
maceutical agent before starting thrombolytic therapy and to
perform scintigraphy even 3 to 4 h later without interfering
with the treatment and at a time when the patient's condition
is relatively stabilized. In our study, the time lapse between
admission to the coronary care unit and start of intravenous
rt-PA infusion ranged from 15 to 35 min and in no case could
the delay be attributed to the tracer reconstitution or injec-
tion procedure. The delay in scintigraphic acquisition re-
duces the potential problems associated with patient trans-
port to the nuclear medicine department, which is necessary
when SPECT imaging is employed.
Life-threatening arrhythmias dependent on acute myo-
cardial ischemia or reperfusion are more likely to occur in
the first few hours after admission (45). In two of our
patients, sustained ventricular tachycardia occurred before
the planned time of the first scintigraphic study. Only in Case
6, a patient with inferior myocardial infarction and AV
block, was an intervention (cardiac pacing) outside the
coronary care unit necessary to correct bradycardia.
Perfusion defect in the scintigraphic study performed be·
fore thrombolytic treatment as expression of the ischemic area
at risk. Perfusion defects were present in all patients on the
scintigrams performed after the injection of technetium-99m
isonitrile before the start of thrombolytic treatment. The
location of the defects was consonant with the ECG and
echocardiographic results. Experimental data support the
reliability of the perfusion defect estimated from the isoni.
trile images as an indicator of the size of myocardium at risk
after coronary occlusion. In dogs undergoing permanent or
2 h coronary occlusion followed by reperfusion, the size of
the scintigraphic perfusion defect during occlusion corre-
sponded to the occluded vascular bed quantified by a post-
mortem technique that included nonoccluded coronary ar-
tery dye perfusion (46). Li et al. (47) showed a high
correlation coefficient (r = 0.96) between tissue technetium-
99m isonitrile content and coronary flow assessed using
labeled microspheres in dogs during coronary occlusion,
with perfusion defects in the myocardial regions correspond-
ing to the abnormal distribution of the microspheres. In 38
patients with coronary artery disease, Dilsizian et al. (48)
demonstrated that isonitrile imaging accurately predicts cor·
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Figure 3. Patient I, Admission (A) and 5 day (B)
tomographic images. Top row, Vertical long-axis
view from lateral (left) to septal (right) wall. Middle
row, Horizontal long-axis view from anterior (left)
to inferior (right) wall. Bottom row, Short-axis view
from basal (left) to subapical (right) wall. The
anteroseptal perfusion defect present in A(arrows)
has almost completely disappeared in B (73% de-
crease).
onary occlusion with poor collateral flow; on the basis of
their results, they suggested that this method could be useful
in evaluating patients with acute myocardial infarction. In
our study, the size of the perfusion defect calculated on the
basis of SPECT imaging, varied from 8.6% to 41.7% of the
left ventricular mass, indicating a wide range of myocardium
at risk.
Pedusion defect in the post-thrombolytic scintigram and
final infarct size. Experimental data (47,49,50) obtained in
dogs that underwent prolonged coronary occlusion followed
by reperfusion are conflicting with respect to the possibility
that early isonitrile imaging would accurately reflect regional
coronary flow and myocardial viability in the reperfused
myocardium. Consequently, the real extent of myocardial
infarction could not be pr~cisely quantifie4 by scintigraphic
evaluation performed immediately after treatment. There-
fore, to avoid an erroneous estimate of the extent of the
infarcted area, scintigraphy performed after thrombolytic
treatment must be performed with some· delay after the
intervention. Our de~ision to perform the second scinti-
graphic study 5 days after the acute~vent was based on the
arbitrary assumption that 5 days is an adequate amount of
time for this technique to ensure an accurate assessment of
infarct size. It is possible that a shorter time delay may be
sufficient; experimen.tal data by Verani et al. (46) demon-
strated good evaluation of infarct size using tomographic
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Figure 4. Patient 4. Same image sequence as in
Figure 3. A large uptake defect involving the septal,
anterior and apical walls is shown (arrows). No
significant changes from admission (A) to 5 day
imaging (B) occurred (6% decrease).
scintigraphy performed 48 h after reperfusion. In contrast,
Gregoire et al. (51) showed a progressive reduction in
scintigraphic defect score from a first tomographic study at
24 h to a later study after 7 days in patients with acute
myocardial infarction who received thrombolytic therapy.
Therefore more frequent scintigraphic control studies are
needed to further define the optimal time for final infarct size
quantification. On the basis of the available data, however, 5
days after the acute event may be a reasonable compromise
that combines early evaluation and accurate assessment of
infarct size.
In our study, perfusion defects were present in all pa-
tients in the scintigraphic study performed 5 days after
admission. Seven patients showed a significant reduction in
the extent of the defect when compared with the initial size:
the reduction of the involved left ventricular mass ranged
from 51% to 73%; in the remaining six patients, only a
minimal reduction (varying from I% to 8%) of the extent of
the perfusion defect could be demonstrated. Infarct size
determined on the basis of the postthrombolytic treatment
scintigrams showed a good correlation with the amount of
necrotic tissue evaluated using the MB CK curve.
Our results in humans agree with those of an experimen-
tal study in dogs (46), which showed that in the latter study,
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Figure 7. Evolution of the asynergic area extent score in the 5 day
(left) and 1month (right) echocardiogram compared with the percent
decrease in the scintigraphic perfusion defect size in 13 patients.
graphic data corresponded to the difference between the
myocardial area vascularized by the occluded vascular bed
and the anatomic infarct size.
Preliminary data in humans suggest the usefulness of
technetium-99m isonitrile myocardial tomography in assess-
ing the response to thrombolytic treatment in acute myocar-
dial infarction (52-57). In our study, ofthe seven patients in
whom a remarkable decrease in the perfusion defect was
present, reperfusion could be inferred on the basis of non-
invasive findings in three; all seven subjects had a patent
infarct-related vessel at coronary angiography. In all of these
patients, echocardiography performed I month later demon-
strated a reduction in wall motion abnormalities, with a
decrease of 33% to I()()% in asynergic area extent score. In
contrast, of the six patients who had a limited or negligible
reduction in the perfusion defect size, noninvasive findings
were suggestive of absent rellow in three, and in four
subjects, coronary angiography demonstrated the occlusion
of the infarct-related vessel. In these six patients, there was
no detectable echocardiographic improvement in left ven-
tricular wall motion, even after I month. Our data, which
demonstrate a strict correlation between scintigraphic re-
sults and myocardial functional recovery, suggest that the
decrease in scintigraphic defect size between the pre- and
the postthrombolytic treatment scintigraphic images is really
an expression of the amount of salvaged myocardium.
Reliability of conventional methods to assess the results of
thrombolytic therapy in the individual patient. The impor-
tance of the opportunity offered by isonitrile tomography to
"measure" the benefit obtained by the individual patient
after thrombolytic therapy is emphasized by the absence of
other reliable methods. Coronary angiography, apart from
its invasiveness, can reliably demonstrate infarct-related
vessel patency, but this does not necessarily imply myocar-
dial salvage. In two of our patients, the absence of a
significant decrease in perfusion defect, associated with a
lack of late functional recovery, was demonstrated in the
1008060
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Figure 6. Correlation between the percent decrease in the echocar-
diographic asynergic area extent score and the scintigraphic perfu-
sion defect size in 13 patients.
myocardial imaging with technetium-99m hexakis 2-
methoxyisobutyl isonitrile reliably evaluated infarct size,
especially when the perfusion defect was estimated using
SPECT imaging, which is less influenced by the overlap of
normal and abnormal myocardium than is planar imaging. In
another study in humans by Gibbons et aI. (52), the extent of
hypoperfused myocardium calculated on the basis of SPECT
imaging performed 6 to 14 days after acute myocardial
infarction correlated significantly with the ejection fraction
at rest and with the regional wall motion score in the infarct
segments, indicating its validity as a measure of infarct size.
Decrease in scintigraphic defect size, reperfusion and as·
sessment of salvaged myocardium. If the perfusion defect on
the initial scintigrams can be assumed to reflect the extent of
myocardium at risk and the residual perfusion defect on the
scintigram obtained 5 days later can be considered as an
estimate of infarcted myocardial tissue, then the difference
between the original perfusion defect and the residual defect
is the scintigraphic expression of the amount of salvaged
myocardium. This correspondence has been experimentally
demonstrated in another study (46) in which the amount of
salvaged myocardium calculated on the basis of scinti-
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presence of a patent infarct-related vessel. In these patients,
late reperfusion, which was probably not related to the
thrombolytic treatment and was not effective in salvaging
myocardium, can be presumed to have occurred.
Other noninvasive techniques proposed for the evalua-
tion of the results ofthrombolytic treatment have important
limitations. The ECG does not appear to be helpful in the
identification of patients in whom significant myocardium
salvage occurs as a result of reperfusion. Although several
studies (58-61) indicate that statistically significant differ-
ences exist for Rand Q wave changes between patient
groups with successful or unsuccessful reperfusion, the
ability to recognize different patterns of evolution on the
basis of ECG data is limited in the individual patient (61). In
our series, all but two patients developed Q waves after
thrombolytic treatment, and an overlap in the QRS score
was present between patients in whom scintigraphy showed
a reduction in the original perfusion defect and those whose
perfusion defect remained unchanged.
The usefulness of the early evaluation of left ventricular
function to assess the results of thrombolytic therapy is also
limited. Several studies (62-65) that compared function
measured before and soon after successful thrombolytic
therapy found no early recovery in either regional or global
function. Instead, it has been found that return of contractile
function in the salvaged tissue may require a long time: the
"stunned" myocardium (66) needs this time to repair dam-
aged metabolic processes or to reconstitute high energy
phosphate stores (67,68). In our patients, two-dimensional
echocardiograms performed 5 days after admission demon-
strated the presence of regional asynergy in all but one
subject. In these patients, comparison with echocardiograms
recorded on admission before thrombolytic therapy failed to
reveal any improvement in the asynergic area extent score
despite the reduction in scintigraphic perfusion defect size.
Problems related to the imaging techniques. Technical
problems encountered in performing an accurate quantita-
tive assessment of the cardiac scintigraphic images cannot
be denied. The movements of the heart in the chest as a
result of breathing and myocardial wall motion during the
cardiac cycle are possible sources of inaccuracy (69). The
use of gated scintigraphy has been proposed to overcome
this limitation, but its real usefulness has been questioned
because of the decrease in collected counts per unit of time
(70). In our study, we could not excessively prolong the
acquisition time because of the condition of the patients,
even though the features of the tracer would have allowed it.
Another limitation is caused by the effects of attenuation and
scatter on image quality, with ensuing decrease in both
counting efficiency and spatial resolution (71,72). However,
several nongated tomographic studies (73-75) have demon-
strated the reliability of this method for quantitative studies
in clinical practice. The possibility of accurate quantification
of infarct volume using tomography with technetium-99m
pyrophosphate has been demonstrated in dogs by Lewis et
al. (76), who found a good correlation with the histologic
estimate, and in humans by Corbett et al. (77) and Jansen et
al. (78), who showed a high correlation, respectively, with
the peak serum CK (r = 0.83) and with the enzymatic infarct
size based on the MB CK curve (r = 0.89).
In our protocol, the bias produced by the limitations just
mentioned and by the partial volume effect (79) is partly
reduced by the fact that we assessed volumes and not tracer
concentrations, that the involved tissue was also expressed
as a percent of left ventricular mass and that we compared
two estimates in the same subject and, therefore, under
similar acquisition and reconstruction conditions. Further-
more, the features of our reconstruction technique must be
considered. Previous experience (42) using phantoms and
brain tomography demonstrated the higher image quality of
our modified iterative algorithm as compared with the fil-
tered backprojection that is usually employed. Even if these
results cannot be simply transferred to the imaging of the
heart without considering the differences due to the peculiar
characteristics inherent in myocardial imaging, the high
quality of the images obtained remains a favorable prereq-
uisite for the application of quantitative measurements. The
distinct contrast between perfused and nonperfused myocar-
dial tissue permitted easy definition of myocardial contours
and uptake defects by computer-assisted manual drawing,
with consequent good interobserver reproducibility. In con-
trast, it must be admitted that our method cannot be consid-
ered a common one. Even if it does not require particularly
sophisticated hardware, the procedure is certainly time-
consuming and its routine use cannot be recommended.
Analysis of regional wall motion on left ventricular an-
giograms and two-dimensional echocardiograms was per-
formed on the basis of the visual assessment of asynergic
segments. Visual evaluation of asynergy has been validated
in many previous studies in acute myocardial infarction
(65,80,81). Although this type of evaluation may introduce a
subjective element, the good interobserver agreement in our
study suggests that the results were not significantly af-
fected.
Limitations of the study. It is possible that the perfusion
defects on the 5 day scintigrams do not exclusively reflect
the extent of myocardial necrosis because a significant
amount of tissue, although hypoperfused, may still be met-
abolically active. Positron emission tomography with 18F_2_
deoxyglucose reveals persistent tissue metabolism in a large
number of segments with a fixed or partially resolving stress
thallium defect. This implies that markers of perfusion may
underestimate the extent of viable tissue in hypoperfused
myocardial segments (82,83). Nevertheless, the impressive
correlation found in our study between 5 day scintigraphic
infarct size and enzymatic infarct size suggests that a large
amount of myocardial tissue involved in the perfusion de-
fects observed on the 5 day scintigrams was really necrotic.
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The use of the enzymatic estimate of infarct size to
confirm scintigraphic quantification may not be ideal. How-
ever, enzymatic evaluation of infarct size has been demon-
strated as having a reliable correlation with anatomic data
(84) and has already been employed to validate quantitative
myocardial assessment using thallium-201 SPECT imaging
(44,85). Although the value of this approach could be par-
tially affected by the effects of reperfusion (86), this appears
to be the only reasonable way to validate scintigraphic
estimates of infarct size in humans.
The reliability of isonitrile tomography in assessing the
effect of thrombolytic treatment on induced reperfusion
must be interpreted cautiously. It is possible that the scinti-
graphic evaluation suggests coronary reopening induced by
treatment when, in fact, reperfusion may be induced by the
spontaneous activation of fibrinolytic factors or, alterna-
tively, by the recruitment of collateral vessels around a
persistent subtotal or total coronary occlusion. This last
hypothesis is at least partially undermined by the demon-
stration at coronary angiography performed within 1week of
infarct-related vessel patency in all seven patients with
scintigraphic defect size reduction.
Practical problems. The extensive applicability of this
protocol may be limited by practical problems. The need to
have the hexakis 2-methoxyisobutyl isonitrile labeled with
technetium-99m promptly after patient admission to the
coronary care unit requires rapid communication first be-
tween the home and the emergency room physician and then
between the latter and the nuclear medicine department. In
our institution, the admission of a patient with chest pain
suggestive of acute myocardial infarction is generally an-
nounced in advance by phone by the city emergency ambu-
lance coordination center; therefore, the nuclear medicine
department can often be informed even before the patient is
admitted to the hospital. Other problems may limit the
general applicability of this procedure to patients with acute
infarction. Such problems are mainly caused by the incon-
stant presence of physicians and technicians in some nuclear
medicine departments, particularly during evenings and hol-
idays, and the difficulty in organizing the transport of pa-
tients with an acute ischemic attack outside of the coronary
care unit. However, the availability of mobile gamma cam-
eras could enable at least planar scintigraphic imaging to be
performed at the bedside without moving the patient from
the emergency room.
Clinical implications. In the present study, we evaluated
the ability of technetium-99m hexakis 2-methoxyisobutyl
isonitrile SPECT imaging to assess the results of throm-
bolytic therapy in individual patients with acute myocardial
infarction. Although myocardial salvage achieved by reper-
fusion is often expressed in terms of left ventricular func-
tional recovery, salvage is primarily an anatomic entity
defined as the reduction in infarct size from that envisaged
should no intervention be undertaken (12,87).
Our data show that the comparison between pre- and
post-thrombolytic treatment tomographic images enables
assessment of salvaged myocardium and allows identifica-
tion of successful versus unsuccessful reperfusion, even in
patients whose other noninvasive findings are inconclusive.
Although these data may not be particularly helpful in acute
patient management strategies because the information is
obtained well after the time when additional therapeutic
options can be considered, their prognostic relevance cannot
be denied. Furthermore, the demonstration that it is possible
to predict late myocardial functional recovery on the basis of
the results of the pre- and post-thrombolytic treatment
scintigraphic evaluation enables the early identification of
patients in whom improvement of left ventricular function is
expected to occur.
Finally, the demonstration of the feasibility of this new
approach in assessing the results of thrombolytic therapy
opens the way to the possible use of this protocol to evaluate
the effect of other therapeutic interventions in patients with
acute myocardial infarction by direct assessment of myocar-
dial salvage and residual infarct extent.
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